Feb 5, 2020
Filippo Petti, CEO, Celyad discusses how the company is broadening precision medicine by developing CAR-T immunotherapies to express a natural killer receptor that can recognize and target multiple ligands expressed in up to 80% of all cancers. Filippo talks about the value to cancer patients of both personalized (autologous) and off the shelf (allogeneic) CAR-T therapies and CYAD-101, Celyad's allogeneic CAR-T therapy, that demonstrated for the first time ever, clinical effectiveness in solid tumors.
#CAR_T #NKCells #cancer #immunotherapy #CellTherapy #solidtumors #Tcell #CYAD101 #allogeneic $CYAD
Sponsored by TREND.Community